According to filings with the U.S. Securities and Exchange Commission, Enable Injections is raising up to $29,999,997.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Enable Injections
Enable Injections is a healthcare innovation company focused on improving the patient treatment experience through its enFuse wearable drug delivery platform. This innovative technology allows for the comfortable and convenient subcutaneous delivery of large volumes of medications, offering a hands-free alternative to intravenous treatments. The enFuse system has garnered industry recognition, receiving awards for its novel technology, business growth, and patient-centric design from publications like Fierce Pharma and PM360. Enable Injections actively collaborates with numerous pharmaceutical partners, including Apellis, CSL, Roche, Sanofi, Serina, Sobi, Veridian, and Incyte, to conduct clinical trials and prepare for the commercial launch of partnered therapies utilizing the enFuse platform. The company recently announced a $30 million investment from Sanofi to accelerate manufacturing capabilities and secured regulatory approval in Saudi Arabia for the EMPAVELI Injector, which is based on enFuse technology.

To learn more about Enable Injections, visit https://enableinjections.com/
Enable Injections Linkedin Page: https://www.linkedin.com/company/enable-injections-llc/

Contact:
Timothy Flaherty, Chief Financial Officer
513-326-2800
https://www.linkedin.com/in/tim-flaherty-bbb4468/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.